Evolus (EOLS) to Release Earnings on Tuesday

Evolus (NASDAQ:EOLS - Get Free Report) will issue its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.

Evolus (NASDAQ:EOLS - Get Free Report) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.05). The business had revenue of $61.00 million during the quarter, compared to analyst estimates of $61.14 million. On average, analysts expect Evolus to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolus Trading Up 0.5 %

EOLS traded up $0.06 during midday trading on Tuesday, reaching $11.77. The company's stock had a trading volume of 671,981 shares, compared to its average volume of 612,486. Evolus has a 1 year low of $7.07 and a 1 year high of $15.43. The firm has a market capitalization of $681.95 million, a price-to-earnings ratio of -10.74 and a beta of 1.45. The stock's 50-day moving average is $13.36 and its 200-day moving average is $11.32.

Insider Transactions at Evolus

In other news, insider David Moatazedi sold 7,706 shares of the business's stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $13.08, for a total value of $100,794.48. Following the completion of the sale, the insider now directly owns 792,416 shares of the company's stock, valued at approximately $10,364,801.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Evolus news, insider Rui Avelar sold 27,603 shares of Evolus stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total value of $384,233.76. Following the transaction, the insider now owns 372,288 shares in the company, valued at approximately $5,182,248.96. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider David Moatazedi sold 7,706 shares of the company's stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $13.08, for a total value of $100,794.48. Following the completion of the sale, the insider now directly owns 792,416 shares of the company's stock, valued at approximately $10,364,801.28. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 49,038 shares of company stock valued at $674,232. 5.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on EOLS shares. Needham & Company LLC restated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research note on Wednesday, April 10th. HC Wainwright reissued a "buy" rating and set a $27.00 target price on shares of Evolus in a research note on Friday, March 1st. Finally, Barclays raised shares of Evolus from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $10.00 to $16.00 in a research report on Monday, January 29th.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.